Believing that
better cells lead to better medicine, VistaGen Therapeutics has been applying
pluripotent stem cell technology toward drug rescue, predictive toxicology and
drug metabolism screening.
VistaGen’s
activities are guided by the belief that the key to making better cells is
strictly controlling the differentiation of human pluripotent stem cells, the
building blocks of all cells in the human body. For more than 15 years, the
company’s stem cell research and development teams and collaborators have
developed proprietary methods for controlling the differentiation of human
pluripotent stem cells and the production and maturation of several specific
types of adult human cells, particularly human heart and liver cells.
VistaGen’s drug
rescue activities are focused on combining its stem cell technology and assay
development expertise with modern medicinal chemistry to produce drug rescue
variants – new, safer chemical variants of once-promising drug candidates that
have positive data supporting their therapeutic and commercial potential, but
that were halted in development by the pharmaceutical companies or university
laboratories because of concerns about potential heart or liver toxicity or
metabolism issues.
In the years since
VistaGen was founded, the California-based biotechnology company has developed
two customized bioassay systems designed to transform drug development by
establishing clinically-predictive, human cell-based toxicology screening at
the front end of the development process, long before animal or human studies:
• CardioSafe 3D™ – This customized
human heart cell bioassay system for screening potential heart toxicity of new
drug candidates uses mature, functional, adult human heart cells produced from pluripotent
stem cells (VSTA-CMs™) to detect a far broader range of potential cardiac
toxicities than the FDA-required hERG assay, and it provides proprietary
cardiac toxicity and quantitative structure-function (QSAR) information to
guide highly-efficient selection and development of proprietary drug rescue
candidates for VistaGen’s pipeline.
• LiverSafe 3D™ – VistaGen is
developing and validating this innovative, three-dimensional in-vitro bioassay
system designed to evaluate liver toxicity and drug metabolism issues.
LiverSafe 3D uses VSTA-heps™, VistaGen’s pluripotent stem cell-derived, mature
adult human hepatocytes (liver cells). VSTA-heps have significantly more
functionally useful life span in culture than primary (cadaver) hepatocytes and
overcome the key problems related to use of primary hepatocytes for in vitro
liver safety toxicity and drug metabolism screening, including: extreme
variation in functional activity; limited supply; unknown health status of
donor; and genetic differences.
VistaGen continues
employ its world-class stem cell differentiation and bioassay development
expertise to expand the scope of its drug rescue, drug discovery and strategic
collaboration opportunities worldwide.
For more
information, visit the company’s website at www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment